Medical management of patients presenting with spontaneous intracerebral hemorrhage (ICH) is focused on blood pressure (BP) management. However, the BP goal to prevent ICH expansion remains controversial. Recent clinical trials have suggested that aggressive BP control is safe but may not have the previously thought benefits.
INTRODUCTION
The primary goal in patients presenting with intracerebral hemorrhage (ICH) is to prevent hemorrhage expansion and the resultant deterioration. Reversal of anticoagulation, and aggressive blood pressure control are considered the cornerstones of ICH management. 1 ICH expansion occurs primarily within 6 hours from initial diagnosis but for 37% of patients it may continue up to 24 hours; an initial systolic blood pressure (SBP) of ≥ 200 mmHg is associated with hematoma expansion and increased mortality. 2 A number of studies demonstrate a correlation between higher initial blood pressures and worse outcome. 2 This, in addition to the lack of supporting evidence regarding the risk of ischemia in the region surrounding the hemorrhage, have led to increasingly lower SBP or mean arterial pressure (MAP) goals in ICH management. 3 Recent clinical trials have suggested that aggressive blood pressure control may not have the previously thought benefits. (Fig. 3) . SBP goal was increased to less than 180 mmHg, which was achieved with an oral antihypertensive regimen. The patient's exam gradually improved, he was able to be extubated and gradually recovered following a 3-week hospital stay.
DISCUSSION
Recently, the INTERACT2 trial demonstrated that aggressive SBP lowering to a goal of less than 140 mmHg is safe and resulted in a small yet significant improvement in clinical outcomes. 4 Based on these findings the 2015 AHA guidelines suggested that acute lowering of SBP to 140 mmHg was safe and could be an effective method to improve functional outcomes. 1 Later, the ATACH-2 trial, which attempted to achieve greater therapeutic benefit by more rapidly achieving the SBP goal when comparing intensive (systolic blood-pressure target of 110 to 139 mmHg) or standard (140 to 179 mmHg) care, was terminated prematurely for futility. Apart from establishing non-superiority of aggressive BP management, the ATACH-2 trial underlined the potential risk of SBP reduction to a goal of < 140 mmHg, demonstrating in a post-hoc analysis, an increased rate of renal adverse events at 7 days in the intense BP control group as opposed to the standard group (9% vs 4%, P=0.002), but no significant difference in the rates in other adverse-events. 6 The ATACH-2 trial failed to show a significant benefit from aggressive SBP control, but no serious adverse events related to treatment were seen within the first 72 hours. Importantly, the guidelines for the treatment for hypertensive emergency suggest SBP reduction of 15-25% of the initial value, in order to avoid endorgan hypoperfusion. 7 Hypertensive individuals have cerebral autoregulation curves shifted to the right and require higher arterial pressures to maintain adequate cerebral blood flow. Hence, aggressive SBP reduction may result in cerebral hypoperfusion. 8 Moreover, excessive unintended decrease in BP in this patient population is common, 9 and the Euro-STAT observational study demonstrated that in 10% of cases intravenous antihypertensive 
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